13 results on '"Hulea, Laura"'
Search Results
2. Biomedical Potential of mTOR Modulation by Nanoparticles.
- Author
-
Hulea, Laura, Markovic, Zoran, Topisirovic, Ivan, Simmet, Thomas, and Trajkovic, Vladimir
- Subjects
- *
MTOR protein , *NANOMEDICINE , *HOMEOSTASIS , *CELL death , *CELL metabolism , *MEDICATION safety - Abstract
Modulation of the mammalian target of rapamycin (mTOR), the principal regulator of cellular homeostasis, underlies the biological effects of engineered nanoparticles, including regulation of cell death/survival and metabolic responses. Understanding the mechanisms and biological actions of nanoparticle-mediated mTOR modulation may help in developing safe and efficient nanotherapeutics to fight human disease. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Serine Deprivation Enhances Antineoplastic Activity of Biguanides.
- Author
-
Gravel, Simon-Pierre, Hulea, Laura, Toban, Nader, Birman, Elena, Blouin, Marie-José, Zakikhani, Mahvash, Zhao, Yunhua, Topisirovic, Ivan, St-Pierre, Julie, and Pollak, Michael
- Subjects
- *
METFORMIN , *BIGUANIDE , *TYPE 2 diabetes , *OXIDATIVE phosphorylation , *CANCER cells - Abstract
Metformin, a biguanide widely used in the treatment of type II diabetes, clearly exhibits antineoplastic activity in experimental models and has been reported to reduce cancer incidence in diabetics. There are ongoing clinical trials to evaluate its antitumor properties, which may relate to its fundamental activity as an inhibitor of oxidative phosphorylation. Here, we show that serine withdrawal increases the antineoplastic effects of phenformin (a potent biguanide structurally related to metformin). Serine synthesis was not inhibited by biguanides. Instead, metabolic studies indicated a requirement for serine to allow cells to compensate for biguanide-induced decrease in oxidative phosphorylation by upregulating glycolysis. Furthermore, serine deprivation modified the impact of metformin on the relative abundance of metabolites within the citric acid cycle. In mice, a serine-deficient diet reduced serine levels in tumors and significantly enhanced the tumor growth-inhibitory actions of biguanide treatment. Our results define a dietary manipulation that can enhance the efficacy of biguanides as antineoplastic agents that target cancer cell energy metabolism. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. CUX1 transcription factors: From biochemical activities and cell-based assays to mouse models and human diseases
- Author
-
Hulea, Laura and Nepveu, Alain
- Subjects
- *
TRANSCRIPTION factors , *CANCER cells , *BIOLOGICAL assay , *GENE expression , *MICRORNA , *CELL proliferation , *DNA replication , *LABORATORY mice - Abstract
Abstract: ChIP-chip and expression analyses indicated that CUX1 transcription factors regulate a large number of genes and microRNAs involved in multiple cellular processes. Indeed, in proliferating cells CUX1 was shown to regulate several genes involved in DNA replication, progression into S phase and later, the spindle assembly checkpoint that controls progression through mitosis. siRNA-mediated knockdown established that CUX1 is required for cell motility. Moreover, higher expression of short CUX1 isoforms, as observed in many cancers, was shown to stimulate cell migration and invasion. In parallel, elevated expression particularly in higher grade tumors of breast and pancreatic cancers implicated CUX1 in tumor initiation and progression. Indeed, transgenic mouse models demonstrated a causal role of CUX1 in cancers originating from various cell types. These studies revealed that higher CUX1 expression or activity not only stimulates cell proliferation and motility, but also promotes genetic instability. CUX1 has also been implicated in the etiology of polycystic kidney diseases, both from a transgenic approach and the analysis of CUX1 activity in multiple mouse models of this disease. Studies in neurobiology have uncovered a potential implication of CUX1 in cognitive disorders, neurodegeneration and obesity. CUX1 was shown to be expressed specifically in pyramidal neurons of the neocortex upper layers where it regulates dendrite branching, spine development, and synapse formation. In addition, modulation of CUX1 expression in neurons of the hypothalamus has been associated with changes in leptin receptor trafficking in the vicinity of the primary cilium resulting in altered leptin signaling and ultimately, eating behavior. Overall, studies in various fields have allowed the development of several cell-based assays to monitor CUX1 function and have extended the range of organs in which CUX1 plays an important role in development and tissue homeostasis. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
5. EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax.
- Author
-
Fooks, Katie, Galicia-Vazquez, Gabriela, Gife, Victor, Schcolnik-Cabrera, Alejandro, Nouhi, Zaynab, Poon, William W. L., Luo, Vincent, Rys, Ryan N., Aloyz, Raquel, Orthwein, Alexandre, Johnson, Nathalie A., Hulea, Laura, and Mercier, Francois E.
- Subjects
- *
CYTARABINE , *VENETOCLAX , *ACUTE myeloid leukemia , *KREBS cycle , *HEMATOLOGIC malignancies , *HOMEOSTASIS - Abstract
Background: Acute myeloid leukemia (AML) is an aggressive hematological cancer resulting from uncontrolled proliferation of differentiation-blocked myeloid cells. Seventy percent of AML patients are currently not cured with available treatments, highlighting the need of novel therapeutic strategies. A promising target in AML is the mammalian target of rapamycin complex 1 (mTORC1). Clinical inhibition of mTORC1 is limited by its reactivation through compensatory and regulatory feedback loops. Here, we explored a strategy to curtail these drawbacks through inhibition of an important effector of the mTORC1signaling pathway, the eukaryotic initiation factor 4A (eIF4A). Methods: We tested the anti-leukemic effect of a potent and specific eIF4A inhibitor (eIF4Ai), CR-1-31-B, in combination with cytosine arabinoside (araC) or the BCL2 inhibitor venetoclax. We utilized the MOLM-14 human AML cell line to model chemoresistant disease both in vitro and in vivo. In eIF4Ai-treated cells, we assessed for changes in survival, apoptotic priming, de novo protein synthesis, targeted intracellular metabolite content, bioenergetic profile, mitochondrial reactive oxygen species (mtROS) and mitochondrial membrane potential (MMP). Results: eIF4Ai exhibits anti-leukemia activity in vivo while sparing non-malignant myeloid cells. In vitro, eIF4Ai synergizes with two therapeutic agents in AML, araC and venetoclax. EIF4Ai reduces mitochondrial membrane potential (MMP) and the rate of ATP synthesis from mitochondrial respiration and glycolysis. Furthermore, eIF4i enhanced apoptotic priming while reducing the expression levels of the antiapoptotic factors BCL2, BCL-XL and MCL1. Concomitantly, eIF4Ai decreases intracellular levels of specific metabolic intermediates of the tricarboxylic acid cycle (TCA cycle) and glucose metabolism, while enhancing mtROS. In vitro redox stress contributes to eIF4Ai cytotoxicity, as treatment with a ROS scavenger partially rescued the viability of eIF4A inhibition. Conclusions: We discovered that chemoresistant MOLM-14 cells rely on eIF4A-dependent cap translation for survival in vitro and in vivo. EIF4A drives an intrinsic metabolic program sustaining bioenergetic and redox homeostasis and regulates the expression of anti-apoptotic proteins. Overall, our work suggests that eIF4A-dependent cap translation contributes to adaptive processes involved in resistance to relevant therapeutic agents in AML. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.
- Author
-
Yongmei Feng, Pinkerton, Anthony B., Hulea, Laura, Tongwu Zhang, Davies, Michael A., Grotegut, Stefan, Yann Cheli, Hongwei Yin, Lau, Eric, Hyungsoo Kim, De, Surya K., Barile, Elisa, Pellecchia, Maurizio, Bosenberg, Marcus, Jian-Liang Li, James, Brian, Hassig, Christian A., Brown, Kevin M., Topisirovic, Ivan, and Ronai, Ze'ev A.
- Subjects
- *
MELANOMA , *TRANSLATION initiation factors (Biochemistry) , *EUKARYOTIC cells , *BRAF genes , *SMALL molecules - Abstract
Disrupting the eukaryotic translation initiation factor 4F (eIF4F) complex offers an appealing strategy to potentiate the effectiveness of existing cancer therapies and to overcome resistance to drugs such as BRAF inhibitors (BRAFi). Here, we identified and characterized the small molecule SBI-0640756 (SBI- 756), a first-in-class inhibitor that targets eIF4G1 and disrupts the eIF4F complex. SBI-756 impaired the eIF4F complex assembly independently of mTOR and attenuated growth of BRAF-resistant and BRAF-independent melanomas. SBI-756 also suppressed AKT and NF-kB signaling, but small-molecule derivatives were identified that only marginally affected these pathways while still inhibiting eIF4F complex formation and melanoma growth, illustrating the potential for further structural and functional manipulation of SBI-756 as a drug lead. In the gene expression signature patterns elicited by SBI-756, DNA damage, and cell-cycle regulatory factors were prominent, with mutations in melanoma cells affecting these pathways conferring drug resistance. SBI-756 inhibited the growth of NRAS, BRAF, and NF1-mutant melanomas in vitro and delayed the onset and reduced the incidence of Nras/Ink4a melanomas in vivo. Furthermore, combining SBI-756 and a BRAFi attenuated the formation of BRAFi-resistant human tumors. Taken together, our findings show how SBI-756 abrogates the growth of BRAFindependent and BRAFi-resistant melanomas, offering a preclinical rationale to evaluate its antitumor effects in other cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. Targeting the translation machinery in cancer.
- Author
-
Bhat, Mamatha, Robichaud, Nathaniel, Hulea, Laura, Sonenberg, Nahum, Pelletier, Jerry, and Topisirovic, Ivan
- Subjects
- *
MESSENGER RNA , *ONCOGENES , *TUMOR suppressor genes , *CANCER cells , *TUMORS - Abstract
Dysregulation of mRNA translation is a frequent feature of neoplasia. Many oncogenes and tumour suppressors affect the translation machinery, making aberrant translation a widespread characteristic of tumour cells, independent of the genetic make-up of the cancer. Therefore, therapeutic agents that target components of the protein synthesis apparatus hold promise as novel anticancer drugs that can overcome intra-tumour heterogeneity. In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. mTOR coordinates protein synthesis, mitochondrial activity and proliferation.
- Author
-
Morita, Masahiro, Gravel, Simon-Pierre, Hulea, Laura, Larsson, Ola, Pollak, Michael, St-Pierre, Julie, and Topisirovic, Ivan
- Published
- 2015
- Full Text
- View/download PDF
9. Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin.
- Author
-
Papadopoli, David, Uchenunu, Oro, Palia, Ranveer, Chekkal, Nabila, Hulea, Laura, Topisirovic, Ivan, Pollak, Michael, and St-Pierre, Julie
- Subjects
- *
DRUG metabolism , *CELL metabolism , *GLUTAMINE , *KREBS cycle , *CANAGLIFLOZIN , *TYPE 2 diabetes - Abstract
• Canagliflozin constrains cell proliferation in the absence of glucose. • Canagliflozin modulates mitochondrial respiration. • Canagliflozin impairs glutamine-mediated anaplerosis through the citric acid cycle. • Canagliflozin mediates antiproliferative response through inhibition of glutamine metabolism. Notwithstanding that high rates of glucose uptake and glycolysis are common in neoplasia, pharmacological efforts to inhibit glucose utilization for cancer treatment have not been successful. Recent evidence suggests that in addition to classical glucose transporters, sodium-glucose transporters (SGLTs) are expressed by cancers. We therefore investigated the possibility that SGLT inhibitors, which are used in treatment of type 2 diabetes, may exert antineoplastic activity by limiting glucose uptake. We show that the SGLT2 inhibitor canagliflozin inhibits proliferation of breast cancer cells. Surprisingly, the antiproliferative effects of canagliflozin are not affected by glucose availability nor by the level of expression of SGLT2. Canagliflozin reduces oxygen consumption and glutamine metabolism through the citric acid cycle. The antiproliferative effects of canagliflozin are linked to inhibition of glutamine metabolism that fuels respiration, which represents a previously unanticipated mechanism of its potential antineoplastic action. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia.
- Author
-
Uchenunu, Oro, Pollak, Michael, Topisirovic, Ivan, and Hulea, Laura
- Subjects
- *
PROTEIN synthesis , *PROTEIN kinases , *RAPAMYCIN , *ENERGY metabolism , *KINASES , *KINASE inhibitors - Abstract
Notwithstanding that metabolic perturbations and dysregulated protein synthesis are salient features of cancer, the mechanism underlying coordination of cellular energy balance with mRNA translation (which is the most energy consuming process in the cell) is poorly understood. In this review, we focus on recently emerging insights in the molecular underpinnings of the cross-talk between oncogenic kinases, translational apparatus and cellular energy metabolism. In particular, we focus on the central signaling nodes that regulate these processes (e.g. the mechanistic/mammalian target of rapamycin MTOR) and the potential implications of these findings on improving the anti-neoplastic efficacy of oncogenic kinase inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. RAS Transformation Requires CUX1-Dependent Repair of Oxidative DNA Damage.
- Author
-
Ramdzan, Zubaidah M., Vadnais, Charles, Pal, Ranjana, Vandal, Guillaume, Cadieux, Chantal, Leduy, Lam, Davoudi, Sayeh, Hulea, Laura, Yao, Lu, Karnezis, Anthony N., Paquet, Marilène, Dankort, David, and Nepveu, Alain
- Subjects
- *
DNA repair , *GUANOSINE triphosphatase , *NEOPLASTIC cell transformation , *CANCER cells , *CYTOLOGY - Abstract
: The base excision repair (BER) that repairs oxidative damage is upregulated as an adaptive response in maintaining tumorigenesis of RAS-transformed cancer cells. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
12. METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis.
- Author
-
Liu, Shuo, Hausmann, Simone, Carlson, Scott Moore, Fuentes, Mary Esmeralda, Francis, Joel William, Pillai, Renjitha, Lofgren, Shane Michael, Hulea, Laura, Tandoc, Kristofferson, Lu, Jiuwei, Li, Ami, Nguyen, Nicholas Dang, Caporicci, Marcello, Kim, Michael Paul, Maitra, Anirban, Wang, Huamin, Wistuba, Ignacio Ivan, Porco, John Anthony, Bassik, Michael Cory, and Elias, Joshua Eric
- Subjects
- *
NEOPLASTIC cell transformation , *METHYLATION , *LUNG cancer , *XENOGRAFTS , *HOMOGRAFTS - Abstract
Summary Increased protein synthesis plays an etiologic role in diverse cancers. Here, we demonstrate that METTL13 (methyltransferase-like 13) dimethylation of eEF1A (eukaryotic elongation factor 1A) lysine 55 (eEF1AK55me2) is utilized by Ras-driven cancers to increase translational output and promote tumorigenesis in vivo. METTL13-catalyzed eEF1A methylation increases eEF1A's intrinsic GTPase activity in vitro and protein production in cells. METTL13 and eEF1AK55me2 levels are upregulated in cancer and negatively correlate with pancreatic and lung cancer patient survival. METTL13 deletion and eEF1AK55me2 loss dramatically reduce Ras-driven neoplastic growth in mouse models and in patient-derived xenografts (PDXs) from primary pancreatic and lung tumors. Finally, METTL13 depletion renders PDX tumors hypersensitive to drugs that target growth-signaling pathways. Together, our work uncovers a mechanism by which lethal cancers become dependent on the METTL13-eEF1AK55me2 axis to meet their elevated protein synthesis requirement and suggests that METTL13 inhibition may constitute a targetable vulnerability of tumors driven by aberrant Ras signaling. Graphical Abstract Highlights • METTL13 is the physiologic eEF1A lysine 55 dimethyltransferase • METTL13 dimethylation of eEF1A stimulates protein synthesis in cancer cells • The METTL13-eEF1A methylation axis fuels Ras-driven tumorigenesis in vivo • METTL13 depletion sensitizes cancer cells to PI3K and mTOR pathway inhibitors Ras-driven cancers ramp up protein synthesis by increasing the GTPase activity of a translation elongation factor through a mechanism that involves METTL13-catalyzed eEF1A dimethylation [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1.
- Author
-
Morita, Masahiro, Prudent, Julien, Basu, Kaustuv, Goyon, Vanessa, Katsumura, Sakie, Hulea, Laura, Pearl, Dana, Siddiqui, Nadeem, Strack, Stefan, McGuirk, Shawn, St-Pierre, Julie, Larsson, Ola, Topisirovic, Ivan, Vali, Hojatollah, McBride, Heidi M., Bergeron, John J., and Sonenberg, Nahum
- Subjects
- *
MTOR protein , *MITOCHONDRIA formation , *SURVIVAL analysis (Biometry) , *INTRACELLULAR tracking , *GENE expression , *APOPTOSIS - Abstract
Summary The mechanisms that link environmental and intracellular stimuli to mitochondrial functions, including fission/fusion, ATP production, metabolite biogenesis, and apoptosis, are not well understood. Here, we demonstrate that the nutrient-sensing mechanistic/mammalian target of rapamycin complex 1 (mTORC1) stimulates translation of mitochondrial fission process 1 (MTFP1) to control mitochondrial fission and apoptosis. Expression of MTFP1 is coupled to pro-fission phosphorylation and mitochondrial recruitment of the fission GTPase dynamin-related protein 1 (DRP1). Potent active-site mTOR inhibitors engender mitochondrial hyperfusion due to the diminished translation of MTFP1, which is mediated by translation initiation factor 4E (eIF4E)-binding proteins (4E-BPs). Uncoupling MTFP1 levels from the mTORC1/4E-BP pathway upon mTOR inhibition blocks the hyperfusion response and leads to apoptosis by converting mTOR inhibitor action from cytostatic to cytotoxic. These data provide direct evidence for cell survival upon mTOR inhibition through mitochondrial hyperfusion employing MTFP1 as a critical effector of mTORC1 to govern cell fate decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.